VX-880 / VP-102
Type 1 Diabetes
Key Facts
About Vertex Pharmaceuticals
Vertex Pharmaceuticals has established itself as a premier, fully integrated biopharmaceutical company with a mission to discover, develop, and commercialize innovative medicines for serious diseases. Its landmark achievement is the creation of a portfolio of CFTR modulators that treat the underlying cause of cystic fibrosis for the majority of patients, generating multi-billion dollar annual revenues. The company's strategy is to reinvest these profits to expand its therapeutic reach through a deep pipeline of 264 candidates, utilizing advanced platforms in gene editing, cell therapy, and precision medicine to address adjacent markets with significant unmet medical need.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |
| Type I Diabetes | Genclis | Discovery |
| Inreda AP® | Inreda Diabetic | Commercial |
| iTOL-101 | iTolerance | Preclinical |